23andMe is known for its direct-to-consumer DNA test kits. Celmatix is a company that focuses on diagnosis and treatment of infertility. Together, these two companies hope to improve fertility outcomes.
23andMe points out that infertility affects a large portion of the population. It is estimated that one in eight couples in the United States are having difficulty conceiving. More research is needed to help medical professionals understand the complex mix of environmental and genetic factors involved with infertility.
Celmatix is the only personalized medicine company that is specifically focused on fertility and women’s health. Celmatix and 23andMe have announced a collaboration that is aimed at improving infertility outcomes.
The collaboration will accelerate the launch of Celmatix’s tests. Those tests will aim to provide physicians with a comprehensive lens on infertility. The tests will also enable the development of early screening tests that will help OBGYN’s identify women who are at risk of premature decline of ovarian function (which has both infertility and broader health implications).
The “big idea” of the Celmatix tests is to create a system in which women know about their fertility even before they start thinking about having children. The information about their DNA could be taken into account when they make decisions about when to have a baby. It could prevent women from unintentionally waiting too long before trying.
The collaboration between the two companies will combine Celmatix’s discovery and annotation of more than 5,200 genetic biomarkers related to infertility potential in humans with 23andMe’s research community. 23AndMe’s massive genetic database includes input from nearly 200,000 men and women who have answered questions about fertility.
Over the years, 23andMe researchers have collected a steady stream of data on female fertility, male fertility, and on couples. In 2015, 23andMe worked with researchers at the University of Cambridge. They found half a dozen genetic variations associated with polycystic ovary syndrome. It is the most common reproductive disorder in women and a common cause of infertility.
What does this mean for genealogists? It means that there is the possibility that the Celmatix tests will enable physicians to identify gene mutations that relate to infertility. This information could be a useful thing to add to your medical family history, especially if the gene mutations happen to “run in the family”.
Members of your family, who are struggling with infertility, may find help via the results of a Celmatix test. The addition of a new baby into the family, of course, gives genealogists one more person to add to their family tree.
Related Articles at FamilyTree.com:< Return To Blog